SQI Diagnostics Systems Inc.

SQI Diagnostics Systems Inc. is a biotechnology company that specializes in developing innovative diagnostic solutions to enhance patient care through advanced multiplexing technology. Founded in 1999, SQI Diagnostics Systems Inc. operates out of Toronto, Canada, focusing on delivering diagnostic technologies that enable high-throughput testing.

The company has undergone strategic pivots to refine its offerings, emphasizing its commitment to improving healthcare outcomes. The details regarding the founders or specific past mergers are not available. The most recent funding round took place on February 15, 2022, and involved a single investment deal. SQI Diagnostics Systems Inc.

focuses on providing advanced diagnostic products that utilize multiplexing technology, allowing for the simultaneous analysis of multiple biomarkers. This capability enhances the efficiency and accuracy of diagnostic testing, catering to healthcare providers aiming to improve patient diagnosis and monitoring. Their services include the development of testing platforms and associated reagents, which are designed to facilitate lab operations and streamline the testing process. SQI Diagnostics Systems Inc.

primarily generates revenue through the sale of its diagnostic testing products and platforms. The company’s financial model is based on direct sales to healthcare providers and laboratories, enabling them to perform comprehensive tests that can improve patient outcomes. Specific revenue figures have not been provided. SQI Diagnostics Systems Inc.

is strategically planning to expand its product offerings by introducing new diagnostic tests targeted for launch in the next two years. The company aims to enter emerging markets, focusing on expanding its presence in North America and Europe by 2024. The funding acquired in the latest investment round will be utilized to support these product developments and market expansion initiatives.